FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2077147848> ?p ?o ?g. }

• W2077147848 endingPage "780" @default.
• W2077147848 startingPage "771" @default.
• W2077147848 abstract "Objective Recent experimental studies in chronic kidney disease have suggested that sympathicolytic drugs, similar to angiotensin II antagonism, limit renal fibrosis independent of blood pressure control. Using the model of acute and normotensive anti-thy1 glomerulonephritis, we analysed the action of β-adrenergic blockade (as compared with angiotensin-converting enzyme inhibition) on renal overexpression of the profibrotic cytokine transforming growth factor (TGF)-β. Methods One day after induction of anti-thy1 glomerulonephritis, rats were given increasing doses of the β-blockers metoprolol or nebivolol (0.1-fold, one-fold, 10-fold and 20-fold of the known blood pressure dose) until day 6 and the 20-fold dose until day 12. Additional animals were treated with a high dose of the angiotensin-converting enzyme inhibitor enalapril. At the end of each experiment, blood pressure and heart rate were recorded, glomerular matrix expansion was scored histologically, and protein expression of TGF-β1, fibronectin and plasminogen activator inhibitor-1 was determined in the supernatant of cultured glomeruli. Results Metoprolol and nebivolol reduced heart rate in a dose-dependent manner. Blood pressure was normal in untreated animals and not significantly affected by either treatment. Compared with untreated nephritic rats, TGF-β1 overexpression was not significantly changed by metoprolol or nebivolol in any dose or treatment period. In contrast, TGF-β1 levels were significantly reduced by enalapril both 6 and 12 days after disease induction (–52 and –63%, respectively). The changes in glomerular matrix score, fibronectin and plasminogen activator inhibitor-1 production closely followed expression of TGF-β1. Conclusions In a model of acute and normotensive glomerular fibrosis, β-adrenergic antagonism does not reduce TGF-β overexpression, suggesting that its pressure-independent antifibrotic action may be limited to chronic renal diseases. The beneficial effect of angiotensin II inhibition even on acute matrix expansion may be a relevant mechanism as to the explanation of its superiority in treating fibrotic renal diseases." @default.
• W2077147848 created "2016-06-24" @default.
• W2077147848 creator A5003445142 @default.
• W2077147848 creator A5006846469 @default.
• W2077147848 creator A5027230884 @default.
• W2077147848 creator A5036932318 @default.
• W2077147848 creator A5046643853 @default.
• W2077147848 creator A5056678212 @default.
• W2077147848 creator A5089061569 @default.
• W2077147848 date "2003-04-01" @default.
• W2077147848 modified "2023-10-17" @default.
• W2077147848 title "Angiotensin-converting enzyme inhibition but not β-adrenergic blockade limits transforming growth factor-β overexpression in acute normotensive anti-thy1 glomerulonephritis" @default.
• W2077147848 cites W1874244373 @default.
• W2077147848 cites W1922117259 @default.
• W2077147848 cites W1964176079 @default.
• W2077147848 cites W1988747733 @default.
• W2077147848 cites W1992447657 @default.
• W2077147848 cites W1993851092 @default.
• W2077147848 cites W2001048683 @default.
• W2077147848 cites W2005876700 @default.
• W2077147848 cites W2011732527 @default.
• W2077147848 cites W2012603495 @default.
• W2077147848 cites W2016972506 @default.
• W2077147848 cites W2029371554 @default.
• W2077147848 cites W2035718064 @default.
• W2077147848 cites W2036105561 @default.
• W2077147848 cites W2049453613 @default.
• W2077147848 cites W2056976690 @default.
• W2077147848 cites W2060335268 @default.
• W2077147848 cites W2066538838 @default.
• W2077147848 cites W2098616191 @default.
• W2077147848 cites W2101143105 @default.
• W2077147848 cites W2119431414 @default.
• W2077147848 cites W2128520582 @default.
• W2077147848 cites W2132158287 @default.
• W2077147848 cites W2165325650 @default.
• W2077147848 cites W2241455767 @default.
• W2077147848 cites W2335187016 @default.
• W2077147848 cites W2414472050 @default.
• W2077147848 cites W3030237074 @default.
• W2077147848 cites W4205373146 @default.
• W2077147848 doi "https://doi.org/10.1097/00004872-200304000-00021" @default.
• W2077147848 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12658024" @default.
• W2077147848 hasPublicationYear "2003" @default.
• W2077147848 type Work @default.
• W2077147848 sameAs 2077147848 @default.
• W2077147848 citedByCount "20" @default.
• W2077147848 countsByYear W20771478482012 @default.
• W2077147848 countsByYear W20771478482013 @default.
• W2077147848 countsByYear W20771478482014 @default.
• W2077147848 countsByYear W20771478482017 @default.
• W2077147848 countsByYear W20771478482020 @default.
• W2077147848 crossrefType "journal-article" @default.
• W2077147848 hasAuthorship W2077147848A5003445142 @default.
• W2077147848 hasAuthorship W2077147848A5006846469 @default.
• W2077147848 hasAuthorship W2077147848A5027230884 @default.
• W2077147848 hasAuthorship W2077147848A5036932318 @default.
• W2077147848 hasAuthorship W2077147848A5046643853 @default.
• W2077147848 hasAuthorship W2077147848A5056678212 @default.
• W2077147848 hasAuthorship W2077147848A5089061569 @default.
• W2077147848 hasConcept C126322002 @default.
• W2077147848 hasConcept C134018914 @default.
• W2077147848 hasConcept C27016395 @default.
• W2077147848 hasConcept C2775940317 @default.
• W2077147848 hasConcept C2779611605 @default.
• W2077147848 hasConcept C2779679481 @default.
• W2077147848 hasConcept C2780675426 @default.
• W2077147848 hasConcept C2781280847 @default.
• W2077147848 hasConcept C2908929049 @default.
• W2077147848 hasConcept C71924100 @default.
• W2077147848 hasConcept C84393581 @default.
• W2077147848 hasConceptScore W2077147848C126322002 @default.
• W2077147848 hasConceptScore W2077147848C134018914 @default.
• W2077147848 hasConceptScore W2077147848C27016395 @default.
• W2077147848 hasConceptScore W2077147848C2775940317 @default.
• W2077147848 hasConceptScore W2077147848C2779611605 @default.
• W2077147848 hasConceptScore W2077147848C2779679481 @default.
• W2077147848 hasConceptScore W2077147848C2780675426 @default.
• W2077147848 hasConceptScore W2077147848C2781280847 @default.
• W2077147848 hasConceptScore W2077147848C2908929049 @default.
• W2077147848 hasConceptScore W2077147848C71924100 @default.
• W2077147848 hasConceptScore W2077147848C84393581 @default.
• W2077147848 hasIssue "4" @default.
• W2077147848 hasLocation W20771478481 @default.
• W2077147848 hasLocation W20771478482 @default.
• W2077147848 hasOpenAccess W2077147848 @default.
• W2077147848 hasPrimaryLocation W20771478481 @default.
• W2077147848 hasRelatedWork W1781372697 @default.
• W2077147848 hasRelatedWork W2008380110 @default.
• W2077147848 hasRelatedWork W2021577809 @default.
• W2077147848 hasRelatedWork W2041956969 @default.
• W2077147848 hasRelatedWork W2076907458 @default.
• W2077147848 hasRelatedWork W2163510728 @default.
• W2077147848 hasRelatedWork W2335386838 @default.
• W2077147848 hasRelatedWork W3146731602 @default.
• W2077147848 hasRelatedWork W4236452249 @default.
• W2077147848 hasRelatedWork W2803386915 @default.
• W2077147848 hasVolume "21" @default.

• next